Advanced search
Publication Cover
Expert Review of Vaccines Volume 21, 2022 - Issue 11
Submit an article Journal homepage
1,862
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza

Ekaterina StepanovaDepartment of Virology, Institute of Experimental Medicine, Saint Petersburg, RussiaView further author information
,
Irina Isakova-SivakDepartment of Virology, Institute of Experimental Medicine, Saint Petersburg, RussiaORCID Iconhttps://orcid.org/0000-0002-2801-1508View further author information
ORCID Icon &
Larisa RudenkoDepartment of Virology, Institute of Experimental Medicine, Saint Petersburg, RussiaCorrespondence[email protected]
View further author information
Pages 1533-1535 | Received 14 Jul 2022, Accepted 23 Aug 2022, Published online: 01 Sep 2022

References

  • Amanatidou E, Gkiouliava A, Pella E, et al. Breakthrough infections after COVID-19 vaccination: insights, perspectives and challenges. Metab Open. 2022;14:100180.
  • Flacco ME, Acuti Martellucci C, Baccolini V, et al. Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis. Eur J Clin Invest. 2022:e13845. DOI:10.1111/eci.13845.
  • Domnich A, Orsi A, Trombetta CS, et al. COVID-19 and seasonal influenza vaccination: cross-protection, co-administration, combination vaccines, and hesitancy. Pharmaceuticals. 2022;15(3):322.
  • Ye Q, Wu M, Zhou C, et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines. 2022;7(1):84.
  • Bommireddy R, Stone S, Bhatnagar N, et al. Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses. Vaccines (Basel). 2022;10(6):944.
  • Cao K, Wang X, Peng H, et al. A single vaccine protects against SARS-CoV-2 and influenza virus in mice. J Virol. 2022;96(4):e0157821.
  • Ao Z, Jing Ouyang M, Olukitibi TA, et al. Development and characterization of recombinant Vesicular Stomatitis Virus (rVSV)-based bivalent vaccine against COVID-19 delta variant and influenza virus. bioRxiv. 2021. 2021.2012.2014.472657.
  • Gerlach T, Elbahesh H, Saletti G, et al. Recombinant influenza A viruses as vaccine vectors. Expert Rev Vaccines. 2019;18(4):379–392.
  • Koonpaew S, Kaewborisuth C, Srisutthisamphan K, et al. A single-cycle influenza A virus-based SARS-CoV-2 vaccine elicits potent immune responses in a mouse model. Vaccines (Basel). 2021;9(8):850.
  • Eiden J, Gordon G, Fierro C, et al. Safety and immunogenicity of M2-deficient, single replication, live influenza vaccine (M2SR) in adults. Vaccines (Basel). 2021;9(12):1388.
  • Loes AN, Gentles LE, Greaney AJ, et al. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. Viruses. 2020;12(9):987.
  • Chen J, Wang P, Yuan L, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bull. 2022;67:1372–1387.
  • Zhu F, Zhuang C, Chu K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10:749–760.
  • Isakova-Sivak I, Tretiak T, Rudenko L. Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. Expert Rev Vaccines. 2016;15(10):1241–1243.
  • Isakova-Sivak I, Stepanova E, Matyushenko V, et al. Development of a T cell-based COVID-19 vaccine using a live attenuated influenza vaccine viral vector. Vaccines (Basel). 2022;10(7):1142.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.